NFKB1 and cancer: Collective data suggest that DET and IDET hold the potential to inhibit both constitutive and inducible (induced by gemcitabine, TNF-α, PMA-, lipopolysaccharide-, IL-1β-, and okadaic acid) NF-κB activation in various cancer cells, therefore illustrating the broad-spectrum of the tumor inhibition activity of these compounds.